Monarch Medical Technologies

Monarch Medical Technologies is a long-established, commercial-stage digital health company with a singular, validated product: the EndoTool® insulin dosing system. The platform uses a proprietary algorithm to personalize insulin therapy for hospitalized patients, aiming to improve glycemic control while minimizing hypoglycemia risk. It has a proven track record with numerous US hospital customers, is supported by clinical evidence, and is positioned to benefit from increasing regulatory focus on inpatient glycemic safety metrics. The company operates as a private entity, generating revenue through its software-as-a-service (SaaS) model for healthcare providers.

EndoTool®: A patient-specific insulin dosing algorithm and software platform for hospital inpatient use. It uses a predictive algorithm to calculate personalized IV and subcutaneous insulin doses, includes analytics dashboards, and delivers clinical advisories to improve glycemic control and reduce hypoglycemia risk.

Monarch competes in the clinical decision support software market for diabetes management, facing potential competition from EHR vendors (e.g., Epic, Cerner) who may offer basic insulin dosing tools, and from other specialized glycemic management software companies. Its key competitive advantages are its long-standing clinical evidence, focus solely on inpatient settings, and a sophisticated algorithm with a 20-year development history.